MLSS
Price
$0.70
Change
+$0.04 (+6.06%)
Updated
May 2, 6:59 PM EST
11 days until earnings call
SRDX
Price
$34.55
Change
+$1.22 (+3.66%)
Updated
May 2, 6:59 PM EST
90 days until earnings call
Ad is loading...

MLSS vs SRDX ᐉ Comparison: Which is Better to Invest?

Header iconMLSS vs SRDX Comparison
Open Charts MLSS vs SRDXBanner chart's image
Milestone Scientific
Price$0.70
Change+$0.04 (+6.06%)
Volume$161.06K
CapitalizationN/A
Surmodics
Price$34.55
Change+$1.22 (+3.66%)
Volume$132.36K
CapitalizationN/A
View a ticker or compare two or three
MLSS vs SRDX Comparison Chart

Loading...

MLSSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SRDXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
MLSS vs. SRDX commentary
May 03, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLSS is a StrongBuy and SRDX is a Buy.

COMPARISON
Comparison
May 03, 2024
Stock price -- (MLSS: $0.70 vs. SRDX: $34.55)
Brand notoriety: MLSS and SRDX are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: MLSS: 241% vs. SRDX: 472%
Market capitalization -- MLSS: $47.46M vs. SRDX: $397.04M
MLSS [@Medical Specialties] is valued at $47.46M. SRDX’s [@Medical Specialties] market capitalization is $397.04M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLSS’s FA Score shows that 0 FA rating(s) are green whileSRDX’s FA Score has 0 green FA rating(s).

  • MLSS’s FA Score: 0 green, 5 red.
  • SRDX’s FA Score: 0 green, 5 red.
According to our system of comparison, SRDX is a better buy in the long-term than MLSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLSS’s TA Score shows that 4 TA indicator(s) are bullish while SRDX’s TA Score has 5 bullish TA indicator(s).

  • MLSS’s TA Score: 4 bullish, 6 bearish.
  • SRDX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SRDX is a better buy in the short-term than MLSS.

Price Growth

MLSS (@Medical Specialties) experienced а +22.11% price change this week, while SRDX (@Medical Specialties) price change was +32.02% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.01%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was +12.85%.

Reported Earning Dates

MLSS is expected to report earnings on Aug 13, 2024.

SRDX is expected to report earnings on Jul 31, 2024.

Industries' Descriptions

@Medical Specialties (+1.01% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for MLSS with price predictions.
OPEN
A.I.dvisor published
a Summary for SRDX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
SRDX($397M) has a higher market cap than MLSS($47.5M). MLSS YTD gains are higher at: 0.884 vs. SRDX (-8.341). SRDX has higher annual earnings (EBITDA): 22.1M vs. MLSS (-6.99M). SRDX has more cash in the bank: 35.2M vs. MLSS (4.62M). MLSS has less debt than SRDX: MLSS (422K) vs SRDX (33.9M). SRDX has higher revenues than MLSS: SRDX (138M) vs MLSS (9.81M).
MLSSSRDXMLSS / SRDX
Capitalization47.5M397M12%
EBITDA-6.99M22.1M-32%
Gain YTD0.884-8.341-11%
P/E RatioN/A71.51-
Revenue9.81M138M7%
Total Cash4.62M35.2M13%
Total Debt422K33.9M1%
FUNDAMENTALS RATINGS
MLSS vs SRDX: Fundamental Ratings
MLSS
SRDX
OUTLOOK RATING
1..100
184
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
9885
PRICE GROWTH RATING
1..100
5064
P/E GROWTH RATING
1..100
10050
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SRDX's Valuation (91) in the Medical Specialties industry is in the same range as MLSS (95). This means that SRDX’s stock grew similarly to MLSS’s over the last 12 months.

MLSS's Profit vs Risk Rating (86) in the Medical Specialties industry is in the same range as SRDX (100). This means that MLSS’s stock grew similarly to SRDX’s over the last 12 months.

SRDX's SMR Rating (85) in the Medical Specialties industry is in the same range as MLSS (98). This means that SRDX’s stock grew similarly to MLSS’s over the last 12 months.

MLSS's Price Growth Rating (50) in the Medical Specialties industry is in the same range as SRDX (64). This means that MLSS’s stock grew similarly to SRDX’s over the last 12 months.

SRDX's P/E Growth Rating (50) in the Medical Specialties industry is somewhat better than the same rating for MLSS (100). This means that SRDX’s stock grew somewhat faster than MLSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MLSSSRDX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 1 day ago
86%
N/A
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 3 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
63%
View a ticker or compare two or three
Ad is loading...
MLSSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SRDXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TSCIX12.15N/A
N/A
AMG TimesSquare Small Cap Growth Z
RCOCX46.66-0.06
-0.13%
Victory RS Large Cap Alpha C
JEPRX13.85-0.02
-0.14%
JPMorgan Equity Premium Income R6
FIIMX23.01-0.04
-0.17%
Fidelity Advisor Mid Cap II I
AMRCX5.13-0.01
-0.19%
American Growth One C

MLSS and

Correlation & Price change

A.I.dvisor tells us that MLSS and SRDX have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MLSS and SRDX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLSS
1D Price
Change %
MLSS100%
+8.75%
SRDX - MLSS
26%
Poorly correlated
+3.66%
VTAK - MLSS
25%
Poorly correlated
-0.13%
ACRS - MLSS
24%
Poorly correlated
+3.97%
PSNL - MLSS
24%
Poorly correlated
+3.23%
ARAY - MLSS
24%
Poorly correlated
-29.03%
More

SRDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRDX has been loosely correlated with LIVN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if SRDX jumps, then LIVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRDX
1D Price
Change %
SRDX100%
+29.69%
LIVN - SRDX
41%
Loosely correlated
+12.32%
KIDS - SRDX
35%
Loosely correlated
+4.76%
RVTY - SRDX
34%
Loosely correlated
+0.13%
SNN - SRDX
34%
Loosely correlated
+0.04%
TMDX - SRDX
32%
Poorly correlated
+24.92%
More